ASH 2021 | Optimizing the efficacy of T-cell based immunotherapies
Nora Zieger
• 10 Dec 2021
Sub-optimal response rates remain an issue in patients with acute lymphocytic leukemia (ALL) treated with blinatumomab, a bispecific T-cell engager (BiTE). Nora Zieger, University Hospital, LMU Munich, Munich, Germany, highlights the importance of improving efficacy of T-cell based immunotherapies. Addition of dasatinib, a Src kinase inhibitor, with blinatumomab is found to improve response rates by potentially preventing T-cell exhaustion. She additionally discusses how treatment-free intervals improved the toxicity profile of flotetuzumab in patients with ALL. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
